Testing immune-therapy for lung cancer and predicting response
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies how well immune checkpoint medicines (with or without chemotherapy) work for lung cancer, and looks for biomarkers—tests that may help predict who benefits. It may help you access a structured treatment plan and additional response testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must understand the study and sign a dated informed consent form.
- You must be 18 years or older.
- You must have lung cancer confirmed by biopsy or test results (tissue or cell sample).
- You must have already received immune checkpoint inhibitor treatment, with or without chemotherapy.
- You must be expected to live at least 12 more weeks.
- You must have measurable tumor spots on scan results (RECIST 1.1) that can be followed.
- You must have adequate blood counts (bone marrow function) and organ function for treatment.
- You must have enough ability and data to track side effects (adverse events).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
This study looks at genetic (DNA) information to find a marker that can help predict whether immunotherapy will work for lung cancer. If you’ve already received an immune checkpoint inhibitor, your tumor/genetic data may be analyzed to look for clues that guide treatment.
This trial tests a personalized immune cell therapy for advanced or relapsed lung cancer. Doctors take your blood, create special T cells that target unique proteins on your cancer, and give them back to you to try to fight the tumor.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
This trial looks at whether adding an immunotherapy drug (an immune checkpoint inhibitor) to chemotherapy helps people with lung cancer live better or respond better. You might be considered if your cancer is confirmed, you can tolerate treatment, and imaging shows measurable spots.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.